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INTRODUCTION
The concept of colony stimulating factor (CSF) as a hema-
topoietic induction, differentiation, and growth factor was first
discussed in 1966 (1). A case of malignancy was later reported
with increased CSF activation in serum and urine in 1974 (2).
Afterwards, it was demonstrated for the first time that CSF was
directly produced in a lung cancer tissue specimen in 1977 (3).
Granulocyte-colony stimulating factor (G-CSF) is recog-
nized as a naturally occurring glycoprotein that stimulates
the proliferation and maturation of precursor cells in the bone
marrow into fully differentiated neutrophils (4). Although
several accounts of G-CSF-producing malignant tumors in
lung cancer exist, few have been observed in the digestive
system. Notably, there have been scarcely any cases found in
primary liver cancer, such as hepatocellular carcinoma (HCC).
Here, we present a rare case of G-CSF-producing HCC that
was confirmed by immunohistochemistry.
CASE REPORT
A 69-yr-old man was admitted to our hospital in July 1999
suffering from fever, general fatigue, weight loss, and right
upper abdominal pain. 
On examination, the patient was 157 cm tall and weighed
43 kg. His temperature was 36.2℃. He showed no signs of
alcohol addiction and had no indications of co-morbidities,
such as diabetes mellitus or dyslipidemia. His family medi-
cal history was clear of any hepatic disorders. He had no signs
of anemia or jaundice in conjunctiva and presented with no
abdominal masses or hepatosplenomegaly, but did complain
of tenderness on the right side hypochondrium. Neurologi-
cal and chest examinations revealed no abnormal findings.
Laboratory tests showed a white blood cell count of 25,450/
mL with 90% neutrophils, a red blood cell count of 367×104/
mL, and a platelet count of 35.2×104/mL. His hemoglobin
value was 10.1 g/dL and hematocrit was 31.2%. Blood chem-
istry showed aspartate aminotransferase of 57 U/L, alanine
aminotransferase of 36 U/L, alkaline phosphatase of 949 U/L
(normal range: 115 to 359 U/L), gamma-glutamyl transpep-
tidase of 313 U/L, cholinesterase of 44 U/L, total protein of
6.7 g/dL, and total albumin of 2.7 g/dL. C-reactive protein
(CRP) was found to be 13.1 mg/dL in serological studies.
The serum level of AFP was 2.0 ng/mL, the level of protein


















Department of Internal Medicine
1, Matsumoto Medical
Center, Matsumoto; Department of Internal Medicine
2,
Division of Gastroenterology and Hepatology, Shinshu




Medical Center, Matsumoto, Japan
Address for Correspondence
Satoru Joshita, M.D.
Department of Internal Medicine, Division of 
Gastroenterology and Hepatology, Shinshu University
School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621,
Japan
Tel : +81-263-37-2634, Fax : +81-263-32-9412
E-mail : joshita@shinshu-u.ac.jp
J Korean Med Sci 2010; 25: 476-80 ISSN 1011-8934
DOI: 10.3346/jkms.2010.25.3.476
A Case of Granulocyte-Colony Stimulating Factor-Producing 
Hepatocellular Carcinoma Confirmed by Immunohistochemistry
Granulocyte-colony stimulating factor (G-CSF) is a naturally occurring glycoprotein
that stimulates the proliferation and maturation of precursor cells in the bone mar-
row into fully differentiated neutrophils. Several reports of G-CSF-producing malig-
nant tumors have been published, but scarcely any in the hepatobiliary system, such
as in hepatocellular carcinoma (HCC). Here, we encountered a 69-yr-old man with
a hepatic tumor who had received right hepatic resection. He showed leukocytosis
of 25,450/mL along with elevated serum G-CSF. Histological examination of surgi-
cal samples demonstrated immunohistochemical staining for G-CSF, but not for
G-CSF receptor. The patient survived without recurrence for four years, but ultimate-
ly passed away with multiple bone metastases. In light of the above, clinicians may
consider G-CSF-producing HCC when encountering patients with leukocytosis and
a hepatic tumor. More cases are needed to clarify the clinical picture of G-CSF-pro-
ducing HCC. 
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was 43 mAU/mL, the level of CEA was 9.9 ng/mL(normal
value: less than 5.0 ng/mL), and the level of CA19-9 was 6.0
U/mL. Tests for hepatitis B virus surface antigen (HBsAg),
hepatitis B core antibody (HBcAb), and hepatitis C virus
antibody were all negative. Elevations in serum G-CSF and
interleukin-6 (IL-6) were seen at 62 pg/mL (normal value:
less than 18.1 pg/mL) and 26.7 pg/mL (normal value: less
than 4.0 pg/mL), respectively. Bone marrow aspiration and
a biopsy specimen revealed hypercellularity of mature neu-
trophils with normal erythropoiesis and megakaryopoiesis.
A hypoechoic tumor 5 cm in diameter was detected by
ultrasonography between the anterior inferior segment (S5)
and anterior superior segment (S8) of the liver. The tumor
presented as a slightly low density area in pre-contrasted com-
puted tomography (CT). It was enhanced in early phase con-
trast enhanced CT and accompanied with diffuse enhance-
ment in the surrounding area, and finally washed out in the
late phase with delayed hyper-enhancement in the surround-
ing area (Fig. 1). Magnetic resonance imaging (MRI) showed
low and high intensity nodules in T1 and T2 weighted imag-
ing with fat suppression, respectively. Angiographic exami-
nation showed that the tumor had hypervascularity. We clini-
cally diagnosed the hepatic tumor to be common HCC accord-
ing to these findings and the surrounding area to be secondary
inflammatory change associated with the tumor. 
We initially considered the possibility of co-infection since
the patient had fever, extreme leukocytosis, and high serum
levels of CRP. We intravenously administered 2 g/day sul-
bactam/cefoperazone and 2,400 mg/day clindamycin for 10
days, and then changed treatment to 1 g/day meropenem and
2,400 mg/day clindamycin for 9 days. No effects were seen,
nor could we detect any infective foci in other organ sites by
radiography or CT. Blood cultures were also tested several
times after admission but were all negative for bacteria and
fungus. CT images of the tumor before and after antibiotic
administration did not differ. Based on the above, we con-
cluded that the patient had no co-infections and diagnosed
him as having a paraneoplastic syndrome. 
The patient received right hepatic resection in September
later that year. His blood leukocyte counts decreased to nor-
mal range, and serum G-CSF and IL-6 deceased to 12 pg/
mL and 5.9 pg/mL, respectively. An encapsulated gray-white
nodule with foci of necrosis was seen by cut surface of the
resected liver (Fig. 2A). Resected specimens of tumor histo-
logically revealed that the tumor was a moderately differen-
tiated hepatocellular carcinoma (Fig. 2B). A specimen of liver
parenchyma adjacent to the tumor, which was diffusely en-
hanced by contrast enhanced CT, showed marked infiltra-
tion with neutrophils within the widened sinusoid that rep-
resented congestion (Fig. 2C). The tumor showed positive
staining for hepatocyte paraffin 1 (Hep par 1) and G-CSF
(Anti-G-CSF [Ab-1], mouse monoclonal antibody, Calbio-
chem, Darmstadt, Germany) in the cytoplasm, but was neg-
ative for G-CSF receptor (G-CSF receptor antibody [S-1284],
mouse monoclonal antibody, Abcam, Cambridge, UK) (Fig.
2D-F). We thus diagnosed this tumor as a G-CSF-produc-
ing hepatocellular carcinoma. 
The patient had regular follow-ups for about four years
without any recurrence. He experienced rib pain in 2003
and was diagnosed as having multiple bone metastases by
several imaging examinations. He was admitted to our hos-
pital again for palliative care, and succumbed to his illness
one month later. His serum G-CSF at the time of death was
18 pg/mL and within normal range. 
DISCUSSION
All cases of G-CSF-producing HCC reported in English
literature are listed in Table 1 (5, 6). As G-CSF-producing
Fig. 1. Computed tomography findings. (A) The tumor measuring 5 cm in diameter between the anterior inferior segment (S5) and the ante-
rior superior segment (S8) of the liver showed hyper-enhancement (black arrow heads) in the early phase of dynamic enhanced CT accom-
panied with diffuse enhancement in the surrounding area (white circle). (B) It showed complete washout (black arrow heads) in the late
phase with delayed hyper-enhancement in the surrounding area (white circle). 
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HCC is extremely rare, only two cases have been document-
ed until now. Here, we present the third such case, along with
immunohistochemical proof of G-CSF expression. 
The following findings are indicative of G-CSF producing
tumors: elevation of serum G-CSF and an increased leuko-
cyte count, transient decreases in G-CSF and leukocyte count
to normal ranges after tumor resection, a simultaneous increase
in G-CSF and neutrophil count with tumor recurrence, and
an elevation in G-CSF expression levels in resected specimens
on the basis of immunohistochemical staining or real-time
reverse transcriptase polymerase chain reaction. One direct
way to prove G-CSF production on the tumor cells is by im-
munohistochemical techniques (7). In this case, we could
clearly demonstrate that the hepatic tumor produced G-CSF
by immunohistochemical analysis of specimens taken dur-
ing his operation (Fig. 2E). Extreme leukocytosis and signif-
Fig. 2. Gross and microscopic findings of the tumor. (A) Cut surface of the resected liver showed an encapsulated gray-white nodule (white
arrow heads) with foci of necrosis. The area adjacent to the tumor (white circle) revealed prominent congestion. Non-neoplastic liver parenchy-
ma was not cirrhotic. (B) Microscopic findings showed atypical cells lying in sheets with marked infiltration of neutrophils and lymphocytes,
which were diagnosed as a moderately differentiated hepatocellular carcinoma (H&E, ×20 magnification of the objective lens). (C) Liver
parenchyma adjacent to the tumor, diffusely enhanced by contrast enhanced CT, showed prominent congestion and marked infiltration
with neutrophils within the widened sinusoid (H&E, ×20 magnification of the objective lens). The other parts of liver did not present find-
ings of chronic hepatitis or cirrhosis (not shown). (D) The tumor lesion was stained with hepatocyte paraffin 1 (Hep par 1) (×20 magnifi-
cation of the objective lens). (E) Immunohistochemical examination also showed positive staining for granulocyte-colony stimulating fac-
tor (G-CSF) in the cytoplasm of atypical cells (×20 magnification of the objective lens). (F) Immunohistochemical examination showed




*Prognosis began at diagnosis.
HCV, hepatitis C virus; WBC, white blood cell; G-CSF, granulocyte-colony stimulating factor; IL-6, interleukin-6; M, male; SVR, sustained virological res-











1 (5)  67 M SVR 27,000  521  NT Poorly differentiated   TAE+Chemotherapy 5 months
hepatocellular carcinoma
2 (6)  66 M - 16,600  178  26.4  Poorly differentiated   Radical surgery+TAE 4 months
hepatocellular carcinoma
Our case  69 M - 25,450  62  26.7  Moderately differentiated   Radical surgery 4 yr
hepatocellular carcinoma
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icant elevation of serum G-CSF were also noticed. Further-
more, both serum white blood cell counts and G-CSF levels
decreased after resection of the tumor. In light of these, we
could be sure that this case was G-CSF-producing HCC. 
The prognosis of G-CSF-producing tumors is generally
considered to be poor and depends largely on the primary
disease (8). Such a prognosis was also noted in the previous
two cases of G-CSF-producing HCC. In support of this, G-
CSF was demonstrated to stimulate growth of a non hemato-
poietic malignant cell line in vivo (9) and is considered to
be an autocrine growth factor in rapid tumor proliferation
and metastasis (10-13).
We also performed immunohistochemical staining for the
G-CSF receptor, which yielded negative findings. This is the
first case of G-CSF-producing HCC in which immunohisto-
chemical staining for G-CSF receptor was performed. Although
the localization of the tumor and absence of liver cirrhosis in
this patient may have contributed to a better prognosis, we
can also speculate that the absence of G-CSF receptors in the
patient’s tumor caused a deficiency or absence of autocrine
growth, which led to a more favorable prognosis. In a simi-
lar manner, G-CSF-receptor-positive groups of oral and meso-
pharyngeal squamous cell carcinomas had a significantly lower
disease-free and overall survival rate than G-CSF-receptor-
negative groups (14).
Another difference between our case and previous ones lies
in the degree of tumor cell differentiation seen in histopathol-
ogy; our case showed moderate differentiation, but the oth-
ers were poorly differentiated (Table 1). It may be likely that
local expression and interactions between G-CSF and G-CSF
receptors induce differentiation of HCC cells into an imma-
ture phenotype. 
Lastly, serum values of IL-6 were elevated both in our case
and in case 2 (6). It has been reported that co-production of
G-CSF and IL-6 is associated with the production of IL-1, a
known as inflammatory cytokine, in G-CSF producing can-
cer cell lines (15). High levels of serum IL-6 and CRP in the
present case may have been responsible for the chief complaint
of fever. IL-6 is considered to act as an endogenous pyrogen
(16, 17) that regulates the synthesis of acute phase proteins,
including CRP (18, 19). However, we were unable to clarify
the production of IL-6 (IL-6 [R-49L]: sc-90110, mouse mon-
oclonal antibody, Santa Cruz Biotechnology, Inc., Santa, Cruz,
CA, USA) or expression of IL-6 receptor (gp130 [AN-H2],
sc-9994, mouse monoclonal antibody, Santa Cruz Biotech-
nology, Inc.) immunohistochemically in our case. It is possi-
ble that the antibodies used were not sensitive enough for
this tumor. 
In conclusion, clinicians should consider G-CSF-produc-
ing HCC when encountering patients with leukocytosis and
a hepatic tumor, and radical surgery may provide a more favor-
able prognosis in such instances. Further cases are needed to
clarify the clinical findings of G-CSF-producing HCC.
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